Partnering Opportunities

Mission Therapeutics’ strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.

Through application of its DUB platform, Mission has the potential to explore multiple additional DUB targets relevant to other diseases, in strategic partnerships with other pharmaceutical companies or academics.

Companies with an interest in Mission’s existing pipeline programmes, or parties with an interest in accessing Mission’s DUB platform through a strategic partnership, are encouraged to make contact to discuss partnering opportunities.

Ongoing Collaborations

Mission Therapeutics maintains a broad network of industrial and academic collaborators.


All business development enquiries should be directed to Paul Wallace, Chief Business Officer.